loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Encequidar, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Encequidar

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: 849675-66-7, Hm-30181, Hm30181, Hm-30181-a, Pgp inhibitor hm30181ak, Encequidar [usan]
    Molecular Formula
    C38H36N6O7
    Molecular Weight
    688.7  g/mol
    InChI Key
    AHJUHHDDCJQACA-UHFFFAOYSA-N
    FDA UNII
    K4I4I996O4
    Encequidar is an inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-glycoprotein (P-gp), with adjuvant activity. Upon oral administration, encequidar selectively binds to and inhibits the multidrug resistance (MDR) efflux pump P-gp, which prevents the efflux of various chemotherapeutic agents from intestinal epithelial cells to the gastrointestinal tract. This leads to an increase in both oral bioavailability and therapeutic efficacy. P-gp prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents. Encequidar is not systemically absorbed.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
    2.1.2 InChI
    InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)
    2.1.3 InChI Key
    AHJUHHDDCJQACA-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC
    2.2 Other Identifiers
    2.2.1 UNII
    K4I4I996O4
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide

    2. Hm-30181

    3. Hm30181

    2.3.2 Depositor-Supplied Synonyms

    1. 849675-66-7

    2. Hm-30181

    3. Hm30181

    4. Hm-30181-a

    5. Pgp Inhibitor Hm30181ak

    6. Encequidar [usan]

    7. Hm30181ak

    8. K4i4i996o4

    9. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide

    10. Hm30181a

    11. Hm-30181a

    12. N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide

    13. Unii-k4i4i996o4

    14. 4h-1-benzopyran-2-carboxamide, N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-

    15. 4h-1-benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-

    16. N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-1-benzopyran-2-carboxamide

    17. N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-4h-1-benzopyran-2-carboxamide

    18. V5q

    19. Encequidar [inn]

    20. Encequidar (usan/inn)

    21. Hm-30181 Free Base

    22. Encequidar (hm30181)

    23. Encequidar [who-dd]

    24. Chembl4594298

    25. Schembl13822558

    26. Ex-a3429a

    27. Dtxsid501100387

    28. Bcp25240

    29. Zib67566

    30. Bdbm50567579

    31. Hm 30181a

    32. Mfcd25976625

    33. S3431

    34. Who 10861

    35. Zinc68014383

    36. Cs-6194

    37. Db14070

    38. Sb18921

    39. Ac-36564

    40. As-35283

    41. Hy-13646

    42. P-glycoprotein Inhibitor Hm30181ak

    43. D11782

    44. A857803

    45. Q27281950

    46. 4-oxo-4h-chromen-2-carboxylic Acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl]-phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide

    47. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide

    48. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 688.7 g/mol
    Molecular Formula C38H36N6O7
    XLogP35.8
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count11
    Rotatable Bond Count11
    Exact Mass688.26454751 g/mol
    Monoisotopic Mass688.26454751 g/mol
    Topological Polar Surface Area139 Ų
    Heavy Atom Count51
    Formal Charge0
    Complexity1220
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of breast cancer , Treatment of soft tissue sarcoma

    Post Enquiry
    POST ENQUIRY